In this case scenario, we describe the vilazodone rifampin interaction and what it means for clinical practice. A 46-year-old patient with major depressive disorder has been stable on vilazodone 40 mg once daily for more than a year. The patient reports good adherence and has experienced excellent control of depressive symptoms.
The patient develops a chronic infection requiring prolonged antimicrobial therapy. Rifampin is started as part of the treatment regimen.
Approximately 4 weeks later, the patient returns reporting worsening depressed mood, decreased motivation, fatigue, and loss of interest in activities. The patient denies missed doses of vilazodone and has no major changes in psychosocial circumstances.
The psychiatrist considers increasing the vilazodone dose but first reviews the patient’s medication list.
What is the most likely explanation for the worsening depression?
A. Rifampin inhibits CYP3A4, increasing vilazodone metabolism
B. Rifampin induces CYP3A4, increasing vilazodone metabolism and lowering vilazodone exposure
C. Vilazodone inhibits rifampin metabolism, causing rifampin toxicity
D. Rifampin induces CYP2C19, increasing vilazodone metabolism and lowering vilazodone exposure
Looking for more questions and study materials? BCPS, NAPLEX, BCGP, BCMTMS, BCACP study materials and much more can be found here!
Explanation – Vilazodone Rifampin Interaction
Vilazodone is primarily metabolized by CYP3A4. Rifampin is a strong CYP3A4 inducer. When rifampin is added, CYP3A4 activity increases, resulting in more rapid metabolism of vilazodone and lower systemic exposure. The patient’s worsening depression can therefore represent a pharmacokinetic drug interaction rather than a failure of vilazodone itself.
This is an important interaction to recognize because rifampin is often prescribed for prolonged courses in certain chronic infections. Tuberculosis is a great example of a longer term use of rifampin. The effect is not simply an issue that occurs on the first day of therapy—the enzyme-inducing effect becomes clinically relevant with continued exposure.
When a patient who is stable on vilazodone suddenly develops worsening depression after starting another medication, think about CYP3A4. Rifampin → CYP3A4 induction → increased vilazodone metabolism → decreased vilazodone exposure → possible loss of antidepressant efficacy.
The prescribing information specifically identifies rifampin as a strong CYP3A4 inducer and recommends considering an increase in vilazodone dosage, based on clinical response, when a strong CYP3A4 inducer is used for more than 14 days. The dose can be increased over 1–2 weeks, up to a maximum of 80 mg/day. When the inducer is discontinued, the vilazodone dose should be gradually returned to the original dose over 1–2 weeks.
The key clinical lesson: Before declaring an antidepressant ineffective, review the medication list for a new enzyme inducer. In this vilazodone rifampin interaction case study, rifampin lowered concentrations of vilazodone and caused treatment failure.
0 Comments